Playback speed
10 seconds
Endocrine Therapy in Advanced HR+/HER2- Beyond 2020: Addition of CDK4/6 Inhibition Is the SoC in the 1st and 2nd-Line Setting
By
Dana-Farber Cancer Institute
FEATURING
Erica Mayer
By
Dana-Farber Cancer Institute
FEATURING
Erica Mayer
1,475 views
February 10, 2020
Login to view comments.
Click here to Login